Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03988036
Title A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors West German Study Group
Indications

Her2-receptor positive breast cancer

Therapies

Pembrolizumab + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.